Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2

International Journal of Urology

Volumn 11, Issue 10, 2004, Pages 876-884

  Chatterjee, Shilla ^a   Sung Park, Eun ^a   Soloff, Melvyn S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Growth inhibition; IGFBP 2 suppression; Prostate cancer

Indexed keywords

COMPLEMENTARY RNA; NEUTRALIZING ANTIBODY; SOMATOMEDIN BINDING PROTEIN 2;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

CELL DIVISION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 8544262194     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00898.x     Document Type: Article

References (20)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics. Cancer J. Clinicians 1999; 49: 8-13.
2. Kimura G, Kasuya J, Giannini S et al. Insulin-like growth factor (IGF) system components in human prostate cancer cell lines: LNCap DU145, and PC-3 cells. Int. J. Urol. 1996; 3: 39-46.
3. Thrasher JB, Tennant MK, Twomey PA, Hansberry KL, Wettalaufer JN, Plymate SR. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations. J. Urol. 1996; 155: 999-1003.
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995; 16: 3-34.
5. Oh Y, Yamanka Y, Wilson E, Kim HS, Vorwerck P, Hwa V. IGF-independent actions of IGFBPs. In: Takano K, Hizuka N, Takahashi SI (eds). Molecular Mechanisms to Regulate the Activities of Insulin-Like Growth Factors. Elsevier, Amsterdam 1998, 123-33.
6. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J. Cell. Biochem. 1999; 75: 652-64.
7. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J. Clin. Endocrinol. Metab. 1993; 76: 1031-5.
8. Figueroa JA, Deraad S, Tadlock L, Speights VO, Rinchart JJ. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J. Urol. 1998; 159: 1379-83.
9. Kanety H, Madjar Y, Dagan Y et al. Serum insulin-like growth factor binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 1993; 77: 229-33.
10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
11. Hoeflich A, Lahm H, Blum W, Kolb H, Wolf E. Insulin-like growth factor-binding protein-2 inhibits proliferation of human embryonic kidney fibroblasts and of IGF-responsive colon carcinoma cell lines. FEBS Letters 1998: 329-34.
12. Menouny M, Binoux M, Babajko S. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-beta and retinoic acid. Endocrinology 1997; 138: 683-90.
13. Kanety H, Kattan M, Goldberg I et al. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br. J. Cancer 1996; 73: 1069-73.
14. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int. J. Cancer 2003; 105: 14-19.
15. Wang ZH, Ma J, Zeng BJ et al. Correlation of glioma cell regression with inhibition of insulin-like growth factor 1 and insulin-like growth factor binding protein-2 expression. Neuroendocrinology 1997; 66: 203-11.
16. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Plymate SR. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J. Clin. Endocrinol. Metab. 1996; 81: 3774-82.
17. Hoeflich A, Reisinger R, Lahm H et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: Protector or promoter? Cancer Res. 2001; 61: 8601-10.
18. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J. Biol. Chem. 1993; 268: 26045-8.
19. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 1998; 273: 18347-52.
20. Menouy M, Binoux M, Babajko S. IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenecity. Int. J. Cancer 1998; 77: 874-9.